Comment
Author: Admin | 2025-04-28
Vaccine.desmopressindesmopressin increases toxicity of trametinib by unknown mechanism. Use Caution/Monitor. Decreased desmopressin dose requirements were noted in 2 young patients with cranial diabetes insipidus in whom trametinib was used concurrently with desmopressin.dichlorphenamidedichlorphenamide and trametinib both decrease serum potassium. Use Caution/Monitor.ponesimodponesimod and trametinib both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.siponimodsiponimod and trametinib both increase immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects.Minor (0)Adverse EffectsAdverse effects listed are all grades of severity unless indicated otherwiseNote *: Adverse reactions are for patients treated with dabrafenib and trametinib >10% Monotherapy Increased AST (60%) Rash (57%) Hyperglycemia (50%) Increase ALT (39%) Leukopenia (38%) Anemia (46%) Neutropenia (44%) Diarrhea (43%) Hypoalbuminemia (42%) Hyperphosphatemia (37%) Hyperkeratosis (37%) Headache (32%) Lymphoedema (32%) Pyrexia (28%) Arthralgia (27%) Papilloma (27%) Increased alkaline phosphatase (24%) Alopecia (22%) Palmar-plantar erythrodysesthesia syndrome (20%) Acneiform dermatitis (19%) Stomatitis (15%) Hypertension (15%) Abdominal pain (13%) Hemorrhage (13%) Back pain (12%) Cough (12%) Myalgia (11%) Dry skin (11%) Constipation (11%) BRAF V600E or V600K mutation-positive melanoma* Increased AST (57%) Hyperglycemia (60-63%) Pyrexia (54-63%) Fatigue (59%) Neutropenia (46-47%) Increased ALT (48%) Hypoalbuminemia (25-48%) Anemia (25-43%) Hypophosphatemia (38-42%) Nausea (35-40%) Headache (30-39%) Increased alkaline phosphatase (38%) Rash (32-37%) Chills (31-37%) Diarrhea (31-33%) Lymphopenia (26-32%) Vomiting (27-28%) Arthralgia (25-28%) Hypertension (26%) Hyponatremia (25%) Peripheral edema (21%) Thrombocytopenia (21%) Cough (20%) Myalgia (15-20%) Abdominal pain (18%) Hemorrhage
Add Comment